Susunod

Auto-play

Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma

1 Mga view • 07/18/23
Ibahagi
I-embed
administrator
administrator
Mga subscriber
0

William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.

Magpakita ng higit pa
0 Mga komento sort Pagbukud-bukurin Ayon
Mga Komento sa Facebook

Susunod

Auto-play